 |
caffeine and sodium benzoate |
|---|---|
| Trade Name | |
| Orphan Indication | Seizure prolongation in patients undergoing electroconvulsive therapy |
| USA Market Approval | USA |
| USA Designation Date | 2012-08-22 00:00:00 |
| Sponsor | Luitpold Pharmaceuticals, Inc.;800 Adams Ave., Suite 100;Norristown, Pennsylvania, 19403 |
